

# BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: B/12-B, Industrial Estate, Pologround, Indore-452015 (M.P.)

Tel. 0731-2426700; Email id- bcplcompliance@gmail.com;

Website- www.biofilgroup.net; Fax: 0731-2426700

**Date: 13<sup>th</sup> November, 2025**

To, The Secretary ( <b>DCS/Compliance</b> ), Corporate Relationship Department, <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001	To, The Secretary ( <b>Listing/Compliance</b> ), Corporate Relationship Department, <b>National Stock Exchange of India Limited</b> , Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Mumbai – 400051
--	--

**Subject: Outcome of Board Meeting held on Thursday 13<sup>th</sup> November, 2025 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**Reference: Biofil Chemicals & Pharmaceuticals Limited (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)**

Dear Sir/Madam,

With reference to the above captioned subject and in pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors of the Company in their meeting (Serial No. 06/2025-26) held on today i.e., Thursday, 13<sup>th</sup> Day of November, 2025, has inter alia, considered and approved the following businesses:

1. Un-Audited Financial Results of the Company for the quarter and half year ended on 30<sup>th</sup> September, 2025 along with the Statement of Assets and Liabilities, Cash Flow Statement, limited Review Report thereon. ***(Copy of financial results for the quarter as well as half year ended 30<sup>th</sup> September, 2025 enclosed herewith).***
2. Other routine businesses with the permission of Chair.

Furthermore, copy of Un-Audited Financial Results of the Company shall also be submitted in XBRL mode in integrated filing financials within prescribed time limit from the conclusion of Board Meeting.

The aforesaid Un-Audited Financial Results of the Company shall also be uploaded on the Company's website i.e. [www.biofilgroup.net](http://www.biofilgroup.net) and on the website of the Stock Exchanges i.e. at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com). Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available will be published in Hindi and English Newspapers within prescribed time limit.

The Meeting of the Board of Directors commenced at 04:45 P.M. and concluded at 06:30 P.M.

The above information will also be available on the website of the Company at [www.biofilgroup.net](http://www.biofilgroup.net).

You are requested to please take on record the same.

Thanking you.

Yours Faithfully,

**FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED**

**Apoorv Jain**  
Digitally signed  
by Apoorv Jain  
Date:  
2025.11.13  
18:46:40 +05'30'

**APOORV JAIN**  
**COMPANY SECRETARY & COMPLIANCE OFFICER**  
**M. NO. A71739**

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

To,  
The Board of Directors  
Biofil Chemicals and Pharmaceuticals Limited  
Indore (M.P.)

We have reviewed the accompanying statement of unaudited Standalone Financial results ("the statement") of **Biofil Chemicals and Pharmaceuticals Limited** ("the company") for the quarter ended 30<sup>th</sup> September, 2025 and year to date from 01<sup>st</sup> April 2025 to 30<sup>th</sup> September, 2025 attached herewith. The Statement has been prepared by the Company's Management pursuant to requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the Company's management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with rule 3 of Companies (Indian Accounting Standards) Rules, 2015 (as amended), in compliance with Regulation 33 issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "*Review of Interim Financial Information Performed by Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would be



aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard (Ind AS) and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MAHESHWARI & GUPTA**  
Chartered Accountants  
FRN: 006179C

  
**CA. SUNIL MAHESHWARI**  
Partner  
M. No. 403346



Place: Indore

Date: 13/11/2025

UDIN: 25403346BMIITO8535



( Amount in Lakhs except EPS)

**Statement of Unaudited Financial Results for the quarter and Half Year ended 30th September 2025**

	Particulars	Quarter Ended			Half Year Ended		Previous Year Ended
		3 Month Ended 30/09/2025	3 Month Ended 30/06/2025	Corresponding 3 months ended in the previous year (30/09/2024)	Year to date figures for current period ended (30/09/2025)	Year to date figures for the previous year ended (30/09/2024)	Previous year ended on March 31 2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operation	1354.08	643.26	241.26	1997.34	1085.60	3340.22
II	Other Income	6.34	283.20	1.62	289.54	4.55	30.52
III	<b>Total Income (I + II)</b>	<b>1360.42</b>	<b>926.46</b>	<b>242.88</b>	<b>2286.88</b>	<b>1090.16</b>	<b>3370.74</b>
IV	<b>Expenses</b>						
	(a) Cost of materials consumed	118.19	117.14	42.16	235.33	110.78	531.46
	(b) Purchases of stock-in-trade	707.46	974.06	540.11	1681.52	1283.12	2632.06
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	483.80	(497.91)	(385.34)	(14.11)	(425.43)	(78.91)
	(d) Employee benefits expense	17.80	21.04	18.29	38.84	32.15	78.50
	(e) Finance Cost	0.01	0.93	0.90	0.94	1.97	3.69
	(f) Depreciation and Amortisation Expense	6.60	6.60	9.87	13.20	19.75	37.96
	(g) Other expenses						
	1. Manufacturing Expenses	7.67	11.97	8.01	19.64	19.93	46.46
	2. Administrative Expenses	6.03	15.13	4.41	21.16	16.05	41.55
	3. Selling and Distribution Expenses	1.69	1.26	1.18	2.95	5.75	4.35
	<b>Total expenses (IV)</b>	<b>1349.26</b>	<b>650.21</b>	<b>239.60</b>	<b>1999.47</b>	<b>1064.08</b>	<b>3297.13</b>
V	<b>Profit/ (Loss) before exceptional items and tax (III-IV)</b>	<b>11.17</b>	<b>276.25</b>	<b>3.28</b>	<b>287.41</b>	<b>26.08</b>	<b>73.61</b>
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit/ (Loss) before tax (V - VI)</b>	<b>11.17</b>	<b>276.25</b>	<b>3.28</b>	<b>287.41</b>	<b>26.08</b>	<b>73.61</b>
VIII	<b>Tax expense:</b>						
	(1) Current tax	2.81	35.15	0.84	37.96	6.71	21.00
	(2) Deferred tax Credit/ (Charge)	0.00	0.00	0.00	0.00	0.00	(3.17)
	<b>Total Tax expenses</b>	<b>2.81</b>	<b>35.15</b>	<b>0.84</b>	<b>37.96</b>	<b>6.71</b>	<b>17.83</b>
IX	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00
X	<b>Profit/(Loss) for the period from continuing operation (VII-VIII)</b>	<b>8.36</b>	<b>241.10</b>	<b>2.44</b>	<b>249.45</b>	<b>19.37</b>	<b>55.78</b>
XI	Profit/(Loss) from dis-continued operation before tax	0.00	0.00	0.00	0.00	0.00	0.00
XII	Tax expenses of discontinued operation	0.00	0.00	0.00	0.00	0.00	0.00
XIII	<b>Profit/(Loss) from dis-continued operation after tax (XI-XII)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIV	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00	0.00
XV	<b>Profit/ (Loss) for the period (X+XIII)</b>	<b>8.36</b>	<b>241.10</b>	<b>2.44</b>	<b>249.45</b>	<b>19.37</b>	<b>55.78</b>
XVI	<b>Other Comprehensive Income</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	
	A) (I) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	2.80
	(II) Income Tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	(0.71)
	B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00



XVII	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	8.36	241.10	2.44	249.45	19.37	57.87
XVIII	Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38	1627.38	1627.38
XIX	Reserves (Excluding Revaluation Reserve)						(125.42)
XX	Earnings per equity shares (for continuing operation):						
	(1) Basic (Rs)	0.05	1.48	0.01	1.53	0.12	0.34
	(2) Diluted (Rs)	0.05	1.48	0.01	1.53	0.12	0.34
XXI	Earnings Per Equity Share (for discontinued operation)						
	(1) Basic (Rs)	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted (Rs)	0.00	0.00	0.00	0.00	0.00	0.00
XXII	Earnings Per Equity Share (for continuing & discontinued operation)						
	(1) Basic (Rs)	0.05	1.48	0.01	1.53	0.12	0.34
	(2) Diluted (Rs)	0.05	1.48	0.01	1.53	0.12	0.34

The above Unaudited financial results of "the company" for the 2nd quarter and half year ended 30th September 2025 have been reviewed by the Audit committee and subsequently approved by the Board of Directors in their meeting held on Thursday, 13th Day of November 2025.

1 The above results for the 2nd quarter and half year ended 30th September, 2025 have been reviewed by the statutory auditors of the company in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 who have expressed an unmodified opinion. The company's management has exercised necessary due diligence to ensure that the unaudited financial result provide a true and fair view of its affairs.

2 The Statement of Assets & Liabilities as at September 30, 2025 is annexed with the financial results along with the Cash Flow Statements.

This above unaudited Financial Results have been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India (SEBI) and the Companies (Indian Accounting Standards) Rules, 2015 (Ind-AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments

- 4 a. Pharma Product
- b. Chemicals Division

5 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.

6 The aforesaid un-Audited financial Results will be uploaded on the Company's website [www.biofilgroup.net](http://www.biofilgroup.net) and will also be available on the websites of the Stock exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) for the benefit of shareholders and investors.

Date : 13-11-2025

Place : Indore



FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

  
KETAN SHAH  
CHAIRMAN AND MANAGING DIRECTOR  
( DIN: 08818212)



Reporting of Segment wise Revenue, Results and Capital Employed for quarter and half year ended 30th September 2025

( Amount in Lakhs)

S.No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		3 Month Ended 30/09/2025	Preceeding 3 Month Ended 30/06/2025	Corresponding 3 months ended in the previous year (30/09/2024)	Year to date figures for current period ended (30/09/2025)	Year to date figures for the previous year ended (30/09/2024)	Previous Year ended March 31 2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Segment Revenue</b>						
	Pharma Unit	1,214.47	484.75	182.20	1,699.22	921.84	2,666.04
	Chemicals Division	139.61	158.51	59.06	298.12	163.77	674.18
	<b>Gross Turnover</b>	<b>1,354.08</b>	<b>643.26</b>	<b>241.26</b>	<b>1,997.34</b>	<b>1,085.60</b>	<b>3,340.22</b>
2	<b>Segment Results</b>						
	Pharma Unit	7.22	269.74	(7.02)	276.97	(5.06)	(14.38)
	Chemicals Division	0.46	7.37	11.20	7.83	32.90	87.19
	<b>Total Segment Profit Before Tax</b>	<b>7.68</b>	<b>277.11</b>	<b>4.18</b>	<b>284.80</b>	<b>27.85</b>	<b>72.81</b>
	Interest Income	3.49	0.06	0.00	3.55	0.05	4.42
	Interest Expenses	0.00	0.92	0.90	0.92	1.81	3.62
	Other Unallocable Income net of Expenditure						
	<b>Profit Before Tax</b>	<b>11.17</b>	<b>276.25</b>	<b>3.28</b>	<b>287.42</b>	<b>26.08</b>	<b>73.61</b>
3	<b>Capital Employed</b>						
	<b>Segment Assets (A)</b>						
	Pharma Division	3,842.96	3,481.58	1,994.49	3,842.96	1,994.49	3,472.49
	Chemicals Division	1,693.40	1,627.23	2,111.29	1,693.40	2,111.29	1,623.55
	<b>Total (A)</b>	<b>5,536.36</b>	<b>5,108.81</b>	<b>4,105.77</b>	<b>5,536.36</b>	<b>4,105.77</b>	<b>5,096.04</b>
	<b>Segment Liabilities (B)</b>						
	Pharma Division	3,123.52	2,290.92	1,422.05	3,123.52	1,422.05	2,919.95
	Chemicals Division	264.38	698.62	868.56	264.38	868.56	297.93
	<b>Total (B)</b>	<b>3,387.90</b>	<b>2,989.55</b>	<b>2,290.60</b>	<b>3,387.90</b>	<b>2,290.60</b>	<b>3,217.88</b>
	<b>Total Capital Employed (Segment Assets-Segment Liabilities)</b>						
	Pharma Division	719.45	1,190.66	572.44	719.45	572.44	552.54
	Chemicals Division	1,429.02	928.60	1,242.73	1,429.02	1,242.73	1,325.62
	<b>Total Capital Employed (Segment Assets-Segment Liabilities)</b>	<b>2,148.46</b>	<b>2,119.26</b>	<b>1,815.17</b>	<b>2,148.46</b>	<b>1,815.17</b>	<b>1,878.16</b>

Date : 13-11-2025

Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

  
KETAN SHAH  
CHAIRMAN AND MANAGING DIRECTOR  
( DIN: 08818212)





**Biofil Chemicals and Pharmaceuticals Limited**

Registered Office: B/12-B, Industrial Estate, Pologround, Indore 452015 (M.P.)

CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426700, Website: www.biofilgroup.net

**STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2025**

(Amount in Lakhs)

Particulars	As at 30/09/2025 Unaudited	As at 31/03/2025 Audited
<b>A ASSETS</b>		
<b>1 Non-current assets:</b>		
(a) Property, Plant & Equipment	694.50	834.48
(b) Capital work in Progress		
(c) Investment Property		
(d) Goodwill		
(e) Other Intangible assets		
(f) Intangible Assets under development		
(g) Biological Assets other than bearer plants		
(h) Financial Assets:		
i. Investments		
ii. Trade receivables		
iii. Loans		
iv. Others (to be specified)		
(i) Deferred tax assets (net)		
(j) Other Non- Current Assets	0	6.21
<b>Sub-total - Non-current assets</b>	<b>694.50</b>	<b>840.68</b>
<b>2 Current assets</b>		
(a) Inventories	348.25	334.14
(b) Financial Assets:		
(i) Investment		
(ii) Trade receivables	4077.00	3,831.50
(iii) Cash and cash equivalents	23.44	13.25
(iv) Bank balances other than (iii) above	12.50	12.28
(v) Loans		
(vi) Others (to be specified)		
(c) Current Tax Assest (Net)		
(d) Other Currents Assets	380.66	64.19
<b>Sub-total - Current assets</b>	<b>4,841.86</b>	<b>4,255.36</b>
<b>TOTAL - ASSETS</b>	<b>5,536.36</b>	<b>5,096.04</b>
<b>B EQUITY AND LIABILITIES</b>		
<b>1 Equity</b>		
(i) Equity Share Capital	1627.38	1,627.38
(ii) Other Equity	503.05	250.78
<b>Sub-total- Equity</b>	<b>2130.43</b>	<b>1878.16</b>
<b>2 Liabilities</b>		
<b>Non-current Liabilities :</b>		
a. Financial Liabilities		
(i) Borrowings		
(ia) Lease Liabilities		
(ii) Trade Payable		
(a) total outstanding dues of micro enterprises and small enterprises; and		
(b) total outstanding dues of creditors other than micro enterprises and small Enterprises.		
(iii) other Financial Liabilities (other than those specified in item (b), to be specified)		
b. Provisions		
c. Deferred tax liabilities (net)	33.12	33.12
d. Other Non-current Liabilities		
<b>Sub-total - Non-current liabilities</b>	<b>33.12</b>	<b>33.12</b>
<b>3 Current liabilities</b>		
a. Financial Liabilities		
(i) Borrowings	2.00	47.13
(ia) Lease Liabilities		
(ii) Trade Payables :-		
(a) total outstanding dues of micro enterprises and small enterprises; and		
(b) total outstanding dues of creditors other than micro enterprises and small Enterprises.	3333.42	3,098.78
(iii) other Financial Liabilities [other than those specified in item (C )]	0.00	
b. Other Current Liabilities	0.00	17.86
c. Provisions	37.40	21.00
d. Current Tax Liabilities (Net)		
<b>Sub-total - Current liabilities</b>	<b>3,372.82</b>	<b>3,184.77</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>5,536.36</b>	<b>5,096.04</b>

Date : 13-11-2025

Place : Indore



FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

Ketan Shah  
CHAIRMAN AND MANAGING DIRECTOR  
(DIN: 08818212)



**Biofil Chemicals and Pharmaceuticals Limited**

Registered Office: B/12-B, Industrial Estate, Pologround, Indore 452015 (M.P.)

CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426700, Website: www.biofilgroup.net


**Statement of cash flows for the year half year ended 30th Sept 2025**

( Amount in Lakhs)

Particulars	HALF YEAR ENDED ON 30.09.25	HALF YEAR ENDED ON 30.09.24
	Unaudited	Unaudited
<b>Cash flow from operating activities</b>		
Profit before tax	287.41	26.08
Adjustments to reconcile profit before tax to net cash used in operating activities		
Depreciation of property, plant and equipment	13.20	19.75
Finance cost	0.94	1.97
Impact Considered in OCI		
Loss (Profit) on Sale of Shares/Assets	(281.18)	0.00
<b>Net (gain)/ loss on derivative contracts on account of Ind AS adjustments</b>		
Provision for doubtful advances/ debts	20.37	47.79
Working capital adjustments		
Increase/ (Decrease) in Inventory	(14.11)	(425.43)
(Increase)/ Decrease in Trade Receivable	(245.50)	751.78
(Increase)/ Decrease in other current assets	(316.48)	(53.27)
Increase/ (Decrease) in trade payables	234.64	(485.02)
Increase/ (Decrease) in other financial liabilities	0.00	0.00
Increase/ (Decrease) in other liabilities	(17.86)	(22.93)
Cash generated from operations	(338.94)	(187.07)
Payment of Income Tax/ Provision	(17.59)	(18.92)
<b>Net cash flows from operating activities</b>	<b>(356.53)</b>	<b>(205.99)</b>
<b>Cash flow from investing activities</b>		
Payment for purchase and construction of property, plant and equipment	(7.05)	0.00
Proceeds from sale of property, plant and equipment	415.00	0.00
(Increase)/ Decrease in other bank balances		
Interest received	5.06	0.00
<b>Net cash flows from investing activities</b>	<b>413.01</b>	<b>0.00</b>
<b>Cash flow from financing activities</b>		
Increase/ (decrease) in Borrowings	(45.13)	1.62
Deemed Investment by Holding Company		
Finance cost	(0.94)	(1.97)
<b>Net cash flows from financing activities</b>	<b>(46.07)</b>	<b>(0.35)</b>
<b>Net increase / (decrease) in cash and cash equivalents</b>	<b>10.41</b>	<b>(206.34)</b>
Cash and cash equivalents at the beginning of the year	25.53	228.35
Cash and cash equivalents at the end of the year	35.94	22.01
<b>Increase / (Decrease) in cash and cash equivalents</b>	<b>10.41</b>	<b>(206.34)</b>

Date : 13-11-2025

Place: INDORE



BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

*K. R. Shah*  
**KETAN SHAH**  
 CHAIRMAN AND MANAGING DIRECTOR  
 (DIN 08818212)